MTN-017

A Phase II trial designed to evaluate the rectal safety, drug absorption and acceptability of a reduced glycerin formulation of tenofovir gel, as well as oral Truvada, at sites in Peru, South Africa, Thailand and the U.S., including Puerto Rico. The study enrolled 195 men who have sex with men (MSM) and transgender women. Results, which were reported February 2016, found the gel was safe to use, with participants preferring to use the gel around the time of sex compared to daily use.

 

Results

International Study Finds High Levels of Adherence to Use of Rectal Microbicide Gel

20-October-2016

      

MTN-017 Backgrounder

24-February-2016

  

MTN-017 Q&A

24-February-2016

 

See Also

MTN-017 Study Protocol

 

MTN-017 Study Page

 

Rectal Microbicides – Fact Sheet

17-July -2018

 

International Study Finds Rectal Microbicide Gel Safe When Used Daily and With Sex

24-February-2016

 

VIDEO – The Rectal Revolution is Here

      

Other Study Milestones

Researchers Launch First-Ever Phase II Safety Study of a Rectal Microbicide to Prevent HIV

02-October-2013

 

Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial

3-April-2013

 

MTN and Partners Launch “The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials”

9-January-2013

         

Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use

17-May-2012

  

Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study

5-March-2012

 


Source URL: https://mtnstopshiv.org/news/mtn-017